文献速递免疫规划

2-10岁儿童接种一剂MenACWY-TT结合疫苗后68个月抗体持久性与加强免疫应答

Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine.
PubMed 文献 · Vaccine · 2018-04-30

本研究评估2-10岁健康欧洲儿童接种一剂MenACWY-TT或MenC-CRM197后68个月抗体持久性及加强免疫应答。结果显示MenACWY-TT组对A、W、Y群rSBA滴度≥1:8的持久率超过50%,C群持久率在MenACWY-TT组超过三分之一、MenC-CRM197组超过一半;加强接种MenACWY-TT后所有血清群应答率达100%且耐受良好。

要点

  • 接种一剂MenACWY-TT后68个月,A、W、Y群rSBA滴度≥1:8的儿童比例超过50%。
  • MenC持久率在MenACWY-TT组为33.3%-47.1%,在MenC-CRM197组为50.0%-75.9%。
  • 加强接种MenACWY-TT后所有血清群应答率达100%,耐受良好。

核心结论

  • 接种一剂MenACWY-TT后68个月,对A、W、Y群的抗体持久性(rSBA滴度≥1:8)在超过50.0%的儿童中观察到;对C群,抗体持久性在超过三分之一的MenACWY-TT受种者和超过一半的MenC-CRM197受种者中观察到。
  • 加强接种一剂MenACWY-TT可诱导所有血清群的稳健免疫应答。

研究设计与样本

  • 初始研究(NCT00674583)将2-10岁健康儿童随机分配接种单剂MenACWY-TT或MenC-CRM197。
  • 随访研究呈现接种后32、44、56和68个月的抗体持久性(总体及按2-5岁和6-10岁年龄分层),以及所有参与者在初种后68个月接种MenACWY-TT的免疫原性和安全性。

主要发现

  • 接种后68个月,MenACWY-TT组rSBA滴度≥1:8对C群的持久率:2-5岁组33.3%,6-10岁组47.1%。
  • 接种后68个月,MenC-CRM197组rSBA滴度≥1:8对C群的持久率:2-5岁组50.0%,6-10岁组75.9%。
  • 加强接种MenACWY-TT后所有血清群应答率达100%,且耐受良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated antibody persistence up to 68 months (M) post-vaccination with a quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine (MenACWY-TT) or a licensed monovalent MenC conjugate vaccine (MenC-CRM197) and subsequent booster responses to MenACWY-TT in healthy European children. METHODS: In the initial study (NCT00674583), healthy children, 2-10 years of age, were randomized to receive a single dose of either MenACWY-TT or MenC-CRM197. In the follow-up study, we present the persistence at 32, 44, 56, and 68 M post-vaccination, overall and stratified by age (2-5 and 6-10 years), and the immunogenicity and safety of MenACWY-TT administered to all study participants at M68 post-primary vaccination. RESULTS: At M68, 33.3% (age group 2-5 years) and 47.1% (age group 6-10 years) of the children vaccinated with MenACWY-TT, and 50.0% (age group 2-5 years) and 75.9% (age group 6-10 years) vaccinated with MenC-CRM197 retained titers ≥1:8 for MenC, as assessed by a serum bactericidal assay using rabbit complement (rSBA). In the MenACWY-TT recipients, the percentages of children retaining rSBA titers ≥1:8 for MenA, MenW, and MenY were 81.7%, 47.3% and 66.7% in age group 2-5 years and 91.8%, 58,8% and 76.5% in age group 6-10 years, respectively. The booster dose induced robust responses (100% for all serogroups) and was well-tolerated. CONCLUSIONS: Antibody persistence (rSBA titers ≥ 1:8) for serogroups A, W and Y was observed in more than 50.0% of the children 68 M after receiving one dose of MenACWY-TT; for MenC, antibody persistence was observed in more than one third of MenACWY-TT and more than half of MenC-CRM197 recipients. Vaccination with a booster dose of MenACWY-TT induced robust immune responses for all serogroups.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Knuf M, Helm K, Kolhe D, et al. Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine. Vaccine. 2018. PMID: 29724511. doi:10.1016/j.vaccine.2018.04.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。